Furthermore, cancer-associated fibroblasts and the FGF/FGFR signaling pathway have been implicated in the development of intrinsic and acquired resistance to EGFR TKIs in patients with NSCLC 29–32. This evidence concerns the gene EGFR and non-small cell lung carcinoma.